Stockwatch: The Victimization Of Big Biotech
Early Success In Biotech Raises An Almost Impossible Bar
Alexion is a case study in the travails faced by a biotech with a single blockbuster as it tries to maintain its scale and transform itself into a sustainable business, without blowing billions on bad M&A.
You may also be interested in...
Satralizumab will be boosted by convenience and MS portfolio in increasingly competitive field.
Big pharmaceutical oncology franchise sales generally grew in the third quarter of 2023, but some were transitioning through loss of exclusivity and others were not being helped by their most innovative therapies.
AstraZeneca is the latest GLP-1 agonist aspirant after Novo’s and Lilly’s recent earnings season successes. Already, a segmentation of potential patients and frantic competition among new GLP-1 agonists and drug combinations are emerging.